Jonathan Gerber's research focuses on improving the identification and targeting of stem cells at the root of leukemia and related diseases, with the goal of personalizing therapy and developing better treatments that are more effective and less toxic. The assay that he developed to detect leukemia stem cells was granted a U.S. patent in 2015, and it has since been advanced into a clinical trial.